Program Announcement

Department of Defense Congressionally Directed Medical Research Programs

Breast Cancer Research Program

Idea Award

Funding Opportunity Number: W81XWH-10-BCRP-IDEA

TABLE OF CONTENTS

I.   FUNDING OPPORTUNITY DESCRIPTION

A.   Program Description

The Breast Cancer Research Program (BCRP) was established in fiscal year 1992 (FY92) to promote innovative research focused on eradicating breast cancer. Appropriations for the BCRP from FY92 through FY08 totaled $2.2 billion. The FY09 appropriation is $150 million (M).

The BCRP challenges the scientific community to design innovative research that will foster new directions for, address neglected issues in, and bring new investigators to the field of breast cancer research. The BCRP focuses its funding on innovative projects that have the potential to make a significant impact on breast cancer, particularly those involving multidisciplinary and/or multi-institutional collaborations. The BCRP encourages risk-taking research; however, all projects must demonstrate solid judgment and rationale.

B.   Award Description

The BCRP Idea Award mechanism was first offered in FY93. Since that time, 14,875 Idea Award applications have been received and 1,920 have been recommended for funding.

The Idea Award is designed to promote new ideas that are still in the early stages of development and have the potential to yield highly impactful data and new avenues of investigation. This mechanism supports conceptually innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will accelerate the eradication of breast cancer. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale. The BCRP seeks applications from all areas of basic, translational, clinical, behavioral, and epidemiological research.

***Presentation of preliminary data is not consistent with the intent of the Idea Award mechanism. While the inclusion of preliminary data is not prohibited, the strength of the application should not rely on preliminary data*.**

Innovation and Impact are the most important aspects of the Idea Award.

Innovation: Research deemed innovative may introduce a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale; however, applications that demonstrate exceptional scientific merit but lack innovation do not meet the intent of the Idea Award.

The following list, ***although not all-inclusive***, provides examples of research that is not innovative and will not be considered for funding under this mechanism:

- Proposing a project whose scope is primarily small molecule or genomic/proteomic screening.

- Exploring a previously tested hypothesis in a different cell line or in a new population. For example, transferring a tested hypothesis from a different cancer type into breast cancer.

- Using a published series of in vitro assays to further characterize a model system.

- Incorporating known biomarkers into in vitro or clinical models of breast cancer.

- Investigating the next logical step or continuation of a previous research project.

- Proposing work that is an incremental advancement of published data.

Impact: Research that has high potential impact may significantly accelerate the eradication of breast cancer.

It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate the project's innovation and its potential impact on breast cancer.

COLLABORATIVE OPTION: The Idea Award mechanism encourages applications that include meaningful and productive collaborations between two investigators. The Collaborative Option under the Idea Award mechanism is structured to accommodate two PIs. The Initiating and Partnering PI each have different submission requirements; however, both PIs should contribute to the preparation of a single application. The collaborative partners may have expertise in similar or disparate scientific disciplines but are expected to bring different strengths to the application. New collaborations are encouraged, but not required. The Collaborative Option is designed to support collaborations on completely new research ideas; therefore, merely continuing an existing or previous collaborative research project between two investigators is not considered innovative and does not meet the intent of the Idea Award mechanism. It is the responsibility of the collaborating investigators to describe how their combined expertise in the collaboration will better address the research question and explain why the work should be done together rather than through separate efforts. *Applications submitted by a mentor and postdoctoral trainee as Initiating and Partnering PIs do not meet the intent of the Collaborative Option.*

C.   Eligibility

Investigators at all academic levels (or equivalent) are eligible to submit applications. *Investigators in postdoctoral positions are strongly encouraged to apply.* Refer to General Application Instructions, Appendix 1, for general eligibility information.

D.   Funding

Applications with a **single** PI:

- The maximum period of performance is **2** years.

- The maximum allowable funding for the entire period of performance is $**375,000** in direct costs.

Applications with the **Collaborative Option**:

- A separate award will be made to each PI's institution.

- Maximum period of performance is **2** years.
- Maximum allowable, combined funding for the entire period of performance is **$550,000** for direct costs.
- Applications requesting the higher level of funding that do not include a collaborative PI will have their budget reduced as appropriate

Applications with **population-based studies** (either single or collaborative PIs):

- Maximum period of performance is **5** years.
- Maximum allowable funding for the entire period of performance is **$750,000** for direct costs.

Applications with the **Collaborative Option** or **population-based studies** must include a compelling justification for requesting the increased levels of funding that are allowed.

The applicant may request the entire maximum direct cost amount for a project that may be less than the maximum period of performance.

Regardless of the period of performance proposed, the applicant may not exceed the maximum direct cost. In addition to the direct costs, indirect costs may be proposed in accordance with the organization's negotiated rate agreement.

Within the guidelines provided in the General Application Instructions, funds can cover:

- Salary
- Research supplies
- Equipment
- Clinical costs
- Support for multidisciplinary collaborations
- Travel between collaborating organizations
- Travel costs of up to $1,800 per year to attend scientific/technical meetings.
- Other direct costs as described in the General Application Instructions for the Detailed Budget and Justification.

In addition, funding must be requested for the PI to attend one 3½-day Department of Defense BCRP Era of Hope meeting, which is held to disseminate the results of BCRP-sponsored research.

The Office of the Congressionally Directed Medical Research Programs (CDMRP) expects to allot approximately $34M of the $150M FY10 BCRP appropriation to fund approximately 60 Idea Award applications and $12.3M to fund approximately 15 Idea Awards with the Collaborative Option, depending on the quality and number of applications received. Funding of applications received in response to this Program Announcement/Funding Opportunity is contingent upon the availability of Federal funds for this program.

E.   Award Administration

Awards will be made approximately 4 to 6 months after receiving a funding notification letter, but no later than September 30, 2011. Refer to the General Application Instructions, Appendix 4, for general award administration information.

II.   TIMELINE FOR SUBMISSION AND REVIEW

- **Pre-application Submission Deadline: 5:00 p.m. Eastern time (ET), April 21, 2010**
- **Application Submission Deadline: 11:59 p.m. ET, May 5, 2010**
- **Scientific Peer Review: June 2010**
- **Programmatic Review: September 2010**

Application submissions will not be accepted unless the pre-application process is completed by the pre-application deadline.

III.   SUBMISSION PROCESS

Submission is a two-step process requiring both (1) pre-application submission through the CDMRP eReceipt system (https://cdmrp.org/) and (2) application submission through Grants.gov (http://www.grants.gov/).

Under the Collaborative Option, the Idea Award mechanism is structured to accommodate two PIs. One partner will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI(s) will be identified as the Partnering PI(s). Initiating and Partnering PIs each have different submission requirements; however, all PIs should contribute significantly to the development of the proposed research project including the project narrative, Statement of Work, and other required statements. The Initiating PI must complete the pre-application submission process and submit the contact information for each Partnering PI. Submission of the same research project to different funding opportunities within the same program and fiscal year is discouraged. The Government reserves the right to reject duplicative applications.

PIs and organizations identified in the application should be the same as those identified in the pre-application. If a change in PI or organization is necessary after submission of the pre-application, the PI must contact the eReceipt help desk at help@cdmrp.org or 301-682-5507.

A. Step 1 – Pre-Application Components

All pre-application components must be submitted through the CDMRP eReceipt system by *5:00 p.m. ET on the deadline*.

For the Collaborative Option: The Initiating PI is responsible for submission of all pre-application components.

The pre-application consists of the following components, which are organized in the CDMRP eReceipt system by separate tabs: (Refer to the General Application Instructions for additional information on pre-application submission.)

- **Proposal Information – Tab 1**

- **Proposal Contacts – Tab 2**

- **Collaborators and Conflicts of Interest – Tab 3**

  For the Collaborative Option: The Initiating PI must enter the contact information for each Partnering PI in the Partnering PI section.

- **Required Files – Tab 4**

  Letter of Intent (LOI) Narrative (one-page limit): Provide a brief description of the research to be conducted. LOI Narratives are used for program planning purposes only (e.g., reviewer recruitment) and *will not be reviewed* during either the peer or programmatic review sessions.

- **Submit Pre-application – Tab 5**

- **Other Documents Tab**

  Not applicable.

B. Step 2 – Application Components

Applications are submitted by the Authorized Organizational Representative (AOR) through Grants.gov (http://www.grants.gov/). Applications must be submitted **by *11:59 p.m. ET on the deadline.***

Each application submission must include the completed application package of forms and attachments identified in Grants.gov for this Program Announcement/Funding Opportunity.

If applying under the Collaborative Option, please note that, for contractual reasons, the CDMRP requires separate Grants.gov application package submissions for the Initiating PI and each Partnering PI. Initiating and Partnering PIs will each be assigned unique and separate log numbers by the CDMRP eReceipt system. Each PI must submit his/her Grants.gov application package using only his/her unique log number.

Application Components for Single PIs or for Initiating PIs under the Collaborative Option:

The Grants.gov application package consists of the following components (Refer to the General Application Instructions, Section II.B., for additional information on application submission.):

1. **SF 424 (R&R) Application for Federal Assistance Form:** Refer to the General Application Instructions, Section II.B., for detailed information.

2. **Attachments Form**

   - **Attachment 1: Project Narrative (six -page limit):** Upload as "ProjectNarrative.pdf."

     Throughout the Project Narrative, describe how the proposed research is innovative, and detail the potential impact it may have on breast cancer. Presentation of preliminary data is not required. However, PIs must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the proposal to be competitive.

     Describe the proposed project using the following outline:

     ○ Background: Present the ideas and reasoning behind the proposed work. Cite relevant literature.

     ○ Hypothesis or Objective: State the hypothesis to be tested or the objective to be reached.

     ○ Specific Aims: Concisely explain the project's specific aims to be funded by this proposal.

     ○ Research Strategy: Describe the experimental design, methods, and analyses including appropriate controls in sufficient detail for analysis. Describe the statistical plan, if appropriate, for the research proposed. Address potential problem areas and present alternative methods and approaches. If human subjects or human biological samples will be used, include a detailed plan for the recruitment of subjects or the acquisition of samples, and statistical plan.

   - **Attachment 2: Supporting Documentation.** Start each document on a new page. Combine and upload as a single file named "Support.pdf." If documents are scanned to pdf, the lowest resolution (100 to 150 dpi) should be used. ***Each component has no page limit unless otherwise noted.***

     ○ References Cited: List all relevant references using a standard reference format that includes the full citation (i.e., author(s), year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate). The inclusion of Internet URLs to references is encouraged.

     ○ List of Acronyms and Symbols: Provide a list of acronyms and symbols (e.g., PCR = polymerase chain reaction).

     ○ Facilities, Existing Equipment, and Other Resources: Describe the facilities and equipment available for performance of the proposed project and any additional

facilities or equipment proposed for acquisition at no cost to the US Army Medical Research and Materiel Command (USAMRMC). Indicate if Government-owned facilities or equipment are proposed for use. Reference should be made to the original or present contract under which the facilities or equipment items are now accountable. There is no form for this information.

- ○ Publications and/or Patent Abstracts (five-document limit): Include relevant publication URLs and/or patent abstracts. If publications are not publicly available, then they must be included. Extra items will not be reviewed.

- ○ Letters of Organizational Support: Provide a letter (or letters if applicable), signed by the Department Chair or appropriate organization official, reflecting the laboratory space, equipment, and other resources available for the project.

- ○ Letters of Collaboration (if applicable) (two-page limit per letter): Provide a signed letter from each collaborating individual or organization that will demonstrate that the PI has the support or resources necessary for the proposed work.

- ○ Intellectual and Material Property Plan (if applicable): Provide a plan for resolving intellectual and material property issues among participating organizations.

- **Attachment 3: Technical Abstract (one-page limit):** Upload as "TechAbs.pdf."

  Use the outline below.

  - ○ Background: Present the ideas and reasoning behind the proposed work.

  - ○ Objective/Hypothesis: State the objective/hypothesis to be tested. Provide evidence or rationale that supports the objective/hypothesis.

  - ○ Specific Aims: State the specific aims of the study.

  - ○ Study Design: Briefly describe the study design, including appropriate controls.

  - ○ Innovation: Briefly describe how the proposed project uses innovation to advance the prevention, detection, diagnosis, and/or treatment of breast cancer.

  - ○ Impact: Briefly describe how the proposed project will have an impact on the eradication of breast cancer.

- **Attachment 4: Public Abstract (one-page limit):** Upload as "PublicAbs.pdf."

  - ○ Clearly describe, in a manner readily understood by lay persons, the rationale and objective for the proposal.

    - - Do not duplicate the technical abstract

  - ○ Describe the ultimate applicability of the research.

    - - What types of patients will it help, and how will it help them?

    - - What are the potential clinical applications, benefits, and risks?

    - - What is the projected time it may take to achieve a patient-related outcome?

- ○ If the research is too basic for clinical applicability, describe the interim outcomes.

- ○ What are the likely contributions of this study to advancing the field of research?

- **Attachment 5: Statement of Work (SOW) (three-page limit):** Upload as "SOW.pdf." Refer to the General Application Instructions, Section II.B., for detailed information.

  For the Collaborative Option, each PI must submit an identical copy of a jointly created SOW. The contributions of the Initiating PI and Partnering PI(s) should be noted for each task.

- **Attachment 6: Detailed Budget and Justification (no page limit):** Upload as "Budget.pdf." Use the Detailed Budget and Justification form (available for download on the Full Announcement page in Grants.gov). Refer to the General Application Instructions, Section II.B., for detailed information.

  For the Collaborative Option, Initiating and Partnering PIs must each submit a unique and separate detailed budget and justification.

- **Attachment 7: Subaward Detailed Budget and Justification (if applicable) (no page limit):** Use a separate Detailed Budget and Justification form for each subaward budget. Combine into a single file and upload as "SubBudgets.pdf." Refer to the General Application Instructions, Section II.B., for detailed information.

- **Attachment 8: Impact Statement (one-page limit):** Upload as "Impact.pdf."

  Describe the ultimate vision for how the proposed work, if successful, will accelerate the eradication of breast cancer.

- **Attachment 9: Innovation Statement (one-page limit):** Upload as "Innovation.pdf."

  Summarize how the proposal is innovative. Investigating the next logical step or incremental advancement on published data is not considered innovative. The following examples of ways in which proposals may be innovative, *although not all-inclusive*, are intended to help PIs frame the innovative features of their proposals:

  - ○ Study concept: Investigation of a novel idea and/or research question.

  - ○ Research method or technology: Use of novel research methods or new technologies, including technology development, to address a research question.

  - ○ Clinical interventions: Use of a novel method or technology for preventing, detecting, diagnosing, or treating.

  - ○ Existing methods or technologies: Application or adaptation of existing methods or technologies for novel research or clinical purposes, or for research or clinical purposes that differ fundamentally from those originally intended.

- **Attachment 10: Collaboration Statement (if applicable, one-page limit):** Upload as "Collaboration.pdf."

  For applications submitted under the Collaborative Option only, describe the expertise of the Initiating and Partnering PI. Describe the contribution and the time commitment of each collaborator toward the proposed research project. Describe how the collaborative effort will better address the research question, and explain why the work should be done together rather than through separate efforts.

3. **Research & Related Senior/Key Person Profile (Expanded) Form:** Refer to the General Application Instructions, Section II.B., for detailed information.

   - PI Biographical Sketch (four-page limit): Upload as "Biosketch_LastName.pdf."
   - PI Current/Pending Support (no page limit): Upload as "Support_LastName.pdf."
   - Key Personnel Biographical Sketches (four-page limit each): Upload as "Biosketch_LastName.pdf."
     - Include the Partnering PI, if applying under the Collaborative Option
   - Key Personnel Current/Pending Support (no page limit): Upload as "Support_LastName.pdf."
     - Include the Partnering PI, if applying under the Collaborative Option

4. **Project/Performance Site Location(s) Form:** Refer to the General Application Instructions, Section II.B., for detailed information.

For the Collaborative Option: Application Components for the Partnering PI(s):

The Partnering PI must follow the link in the email from CDMRP eReceipt and complete the registration process prior to the application submission deadline in order to associate his/her grant application package with that of the Initiating PI.

The application submission process for the Partnering PI uses an abbreviated application package of forms and attachments from Grants.gov that includes:

1. **SF 424 (R&R) Application for Federal Assistance Form**

2. **Attachments Form**

   - **Attachment 5: Statement of Work (SOW) (three-page limit):** Upload as "SOW.pdf." Refer to the General Application Instructions for detailed information on completing the SOW. ***Each PI must submit an identical copy of a jointly created SOW. The contributions of the Initiating PI and Partnering PI (s) should be noted for each task.***

   - **Attachment 6: Detailed Budget and Justification:** Use the Detailed Budget and Justification form (available for download on the Full Announcement page in Grants.gov). Upload as "Budget.pdf." ***Initiating and Partnering PIs must each submit a unique and separate detailed budget and justification.***

- **Attachment 7: Subaward Detailed Budget and Justification (if applicable):** Use a separate Detailed Budget and Justification form for each subaward budget. Combine into a single file and upload as "SubBudgets.pdf."

3. **Project/Performance Site Location(s) Form**

IV. INFORMATION FOR APPLICATION REVIEW

A. Application Review and Selection Overview

All applications are evaluated by scientists, clinicians, and consumer advocates using a twotier review process. The first tier is a scientific peer review of applications against established criteria for determining scientific merit. The second tier is a programmatic review that compares applications to each other and makes recommendations for funding to the Commanding General, USAMRMC, based on scientific merit, the overall goals of the program, and specific intent of the award mechanism. The highest scoring applications from the first tier of review are not automatically recommended for funding. Additional information about the two-tier review process used by the CDMRP may be found at http://cdmrp.army.mil/fundingprocess

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Each level of review requires panelists to sign a nondisclosure statement attesting that application and evaluation information will not be disclosed outside the panel. Violations of the non-disclosure statement can result in the dissolving of a panel(s) and other corrective actions. Organizational personnel and PIs are prohibited from contacting persons involved in the review process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization's application. Violations by panelists or PIs that compromise the confidentiality of the review process may also result in suspension or debarment of their employing organizations from Federal awards. Furthermore, it is a crime for Federal officials to disclose confidential information of one party to another third party (Title 18 United States Code 1905).

B. Review Criteria

1. Peer Review: All applications will be evaluated according to the following criteria, which are listed in decreasing order of importance.

- **Innovation**
  - How the research proposes new paradigms or challenges existing paradigms in one or more of the following ways: Concept or question, research methods or technologies, adaptations of existing methods or technologies, and clinical interventions.
  - How the proposed research is a new research idea and not the next logical step or continuation of a previous research project.

- o How the proposed research represents more than an incremental advance upon published data.
- **Impact**
  - o How the research, if successful, might make a significant contribution toward accelerating the eradication of breast cancer.
  - o How the potential gain warrants the perceived risk.
- **Research Strategy and Feasibility**
  - o How the scientific rationale supports the project and its feasibility, as demonstrated by a critical review and analysis of the literature and/or by logical reasoning.
  - o How well the hypotheses or objectives, aims, experimental design, methods, and analyses are developed and integrated into the project.
  - o How well the PI acknowledges potential problems and addresses alternative approaches.
  - ○ For projects applying for the Collaborative Option, whether the added value of working together is justified to accomplish the proposed research.

The following will not be individually scored, but may impact the overall evaluation of the application:

- **Personnel**
  - ○ How the research team's background and expertise are appropriate to accomplish the proposed work.
  - ○ How the levels of effort are appropriate for successful conduct of the proposed work.
  - o For projects applying for the Collaborative Option, how the partners' expertise and levels of effort support the proposed project.
- **Environment**
  - ○ How the scientific environment is appropriate for the proposed research.
  - ○ How the research requirements are supported by the availability of and accessibility to facilities and resources.
  - ○ How the quality and extent of institutional support are appropriate for the proposed research.
- **Budget**
  - ○ Whether the budget is appropriate for the proposed research and within the limitations of this Program Announcement/Funding Opportunity.
- **Application Presentation**
  - ○ How the writing and components of the application influenced the review.

2. Programmatic Review: The following criteria are used by programmatic reviewers to make funding recommendations.

- Ratings and evaluations of the peer reviewers
- Programmatic relevance
- Relative innovation and impact
- Program portfolio composition
- Adherence to the intent of the award mechanism

V.   ADMINISTRATIVE ACTIONS

After receipt of applications from Grants.gov, the following administrative actions may occur:

A.   Rejection

The following will result in administrative rejection of the application:

- Project Narrative exceeds page limit.
- Project Narrative is missing.
- Budget is missing.
- Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).
- Pre-application is not submitted.
- If submitting under the Collaborative Option, Initiating or Partnering PI(s) application is not submitted by the deadline.

B.   Modifications
- Pages exceeding the specified limits will be removed prior to review for all documents other than the Project Narrative.
- Documents not requested will be removed.
- Following the application deadline, you may be contacted by CDMRP via email with a request to provide certain missing supporting documents (excluding those listed in Section V-A, Rejection). The missing documents must be provided by 5:00 p.m. ET on the second full business day following the date the email was sent. Otherwise, the application will be reviewed as submitted.

C.   Withdrawal

The following may result in administrative withdrawal of the application:

- FY10 BCRP Integration Panel (IP) member(s) is found to be involved in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting document. A list of the FY10 BCRP (IP) members may be found at http://cdmrp.army.mil/bcrp/panel10.htm .

- Submission of the same research project to different funding opportunities within the same program and fiscal year.

- The application does not conform to this Program Announcement/Funding Opportunity description to an extent that precludes appropriate review.

- Direct costs as shown on the detailed budget form exceed maximum allowed by this Program Announcement/Funding Opportunity.

- Inclusion of URLs with the exception of links to published references.

D.   Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending institutional investigation. The institution will be requested to provide the findings of the investigation to the US Army Medical Research Acquisition Activity (USAMRAA) Contracting/Grants Officer for a determination of the final disposition of the application.

VI.   CONTACT INFORMATION

A.   CDMRP Program Announcement Help Desk: Questions related to Program Announcement/Funding Opportunity content or submission requirements should be directed to the CDMRP Program Announcement help desk, which is available Monday through Friday from 7:30 a.m. to 4:00 p.m. ET. Submit questions as early as possible. Response times will vary depending upon the volume of inquiries. Every effort will be made to answer questions within 5 working days.

      Phone: 301-619-7079
      Email: cdmrp.pa@amedd.army.mil

B.   CDMRP eReceipt System Help Desk: Questions related to the submission of the pre-application through the eReceipt system should be directed to the CDMRP eReceipt system help desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET.

      Phone: 301-682-5507
      Email: help@cdmrp.org

C.   Grants.gov Contact Center: Questions related to application submission through the Grants.gov portal should be directed to Grants.gov help desk, which is available 24 hours a day, 7 days a week. Please note that the CDMRP Program Announcement and eReceipt system help desks are unable to provide technical assistance regarding Grants.gov submissions.

      Phone: 800-518-4726
      Email: support@grants.gov

Sign up on Grants.gov for "send me change notification emails" by following the link on the Synopsis page for the Program Announcement/Funding Opportunity. If the application package is updated or changed, the original version of the application package may not be accepted by Grants.gov.

VII. APPLICATION SUBMISSION CHECKLIST

Grants.gov Application Components	Action	Single PI (or Initiating PI) Completed	Partnering PI Completed (Collaborative Option)
SF-424 (R&R) Application for Federal Assistance Form	Complete form as instructed		
Attachments Form	Upload Project Narrative (ProjectNarrative.pdf) as Attachment 1		Not Applicable (N/A)
	Upload Supporting Documentation (Support.pdf) as Attachment 2		N/A
	Upload Technical Abstract (TechAbs.pdf) as Attachment 3		N/A
	Upload Public Abstract (PublicAbs.pdf) as Attachment 4		N/A
	Upload Statement of Work (SOW.pdf) as Attachment 5		
	Upload Detailed Budget and Justification (Budget.pdf) as Attachment 6		
	Upload Subaward Detailed Budget and Justification (SubBudgets.pdf) as Attachment 7		
	Upload Impact Statement (Impact.pdf) as Attachment 8		N/A
	Upload Innovation Statement (Innovation.pdf) as Attachment 9		N/A
	Upload Collaboration Statement (if applicable, Collaboration.pdf) as Attachment 10		N/A
Research & Related Senior/Key Person Profile (Expanded)	Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field		N/A
	Attach PI Current & Pending Support (Support_LastName.pdf) to the appropriate field		N/A
	Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field		N/A
	Attach Current & Pending Support (Support_LastName.pdf) for each senior/key person to the appropriate field		N/A
Project/Performance Site Location(s) Form	Complete form as instructed		